Somatuline Autogel To Be Promoted By Tercica
This article was originally published in The Pink Sheet Daily
Executive Summary
Tercica gains the rights to the acromegaly treatment in the U.S. and Canada through a cross-licensing agreement with Ipsen, which receives European rights to Increlex.
You may also be interested in...
Ipsen Acquisition Trifecta Raises North American Stakes
French drug maker takes control of Tercica, Vernalis’ U.S. subsidiary and Octagen’s investigational hemophilia drug OB-1.
Ipsen Acquisition Trifecta Raises North American Stakes
French drug maker takes control of Tercica, Vernalis’ U.S. subsidiary and Octagen’s investigational hemophilia drug OB-1.
Tercica Acromegaly Therapy Will Launch In Two Months
Based on firm's $100 million sales projections, Somatuline Depot likely will be priced at $25,000 per patient.